期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 23, 期 3, 页码 411-415出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2014.873785
关键词
asthma; chronic obstructive pulmonary disease; clinical trials; drugs; lung fibrosis; pulmonary hypertension
资金
- Pulmagen
- Novartis
- AstraZeneca
During 2012, a number of respiratory drug projects and individual agents were discontinued, for a variety of reasons, including toxicity, lack of efficacy, commercial re-evaluation and change in corporate focus. These included three antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2), which had been evaluated in allergic respiratory disease and (in one case) chronic obstructive pulmonary disease (COPD), and other agents intended for the treatment of asthma, COPD, pulmonary hypertension and lung fibrosis. These have been reviewed against the background of a general reduction in respiratory research by the pharmaceutical industry.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据